Donate For Public and Patients Store Search

S053 - Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management

Monday, March 4; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • 1. Recognize the physical lesions that constitute hidradenitis suppurativa/acne inversa, their characteristic distribution, and their tendency to recur over time.
  • 2. Select appropriate preventive, medical and surgical therapies for patients with hidradenitis suppurativa.

Description

This is an educational session for general dermatologists. This session will cover a review of the epidemiology and comorbidities of HS, diagnosis of HS and phenotypes, and current concepts of HS pathogenesis. A general approach to medical treatment will be discussed, including topical, intralesional, and oral treatments, as well as biologics. Surgical procedures for HS will be presented by a dermatologic surgeon, as well as when to refer to a surgeon. The importance of a multi-specialty approach, lifestyle modifications, and role of support groups will be discussed. There will be a Q&A session with the faculty.

Disclosures

  • Alavi, Afsaneh, MD: AbbVie – A(H), I(Grants/Research Funding), Speaker/Faculty Education(Grants/Research Funding); Actelion – A(Fees); Asana Biosciences, LLC – I(Grants/Research Funding); Boehringer Ingelheim – I(Fees); Canadian Dermatology Association – B(NC); Celgene – SP(Fees); Dermavant Sciences – I(Fees); DS Biopharma – I(Fees); Eli Lilly and Company – I(Fees); Galderma Canada, Inc – A(H), I(Fees); Glenmark Generics Inc. – I(Fees); Incyte Corporation – I(Fees); InflaRx – I(Fees); Janssen Pharmaceuticals, Inc – A(H); LEO Laboratories Ltd (LEO Pharma) – SP(Fees); Leo Pharma Inc – I(Fees); Novartis – I(Fees); Regeneron – I(Grants/Research Funding); UCB – I(Fees); Valeant Pharmaceuticals North America LLC – A(H); XOMA (US) LLC – I(Grants/Research Funding);
  • Garg, Amit, MD: AbbVie – A(H), I(Grants/Research Funding); Asana Biosciences, LLC – A(H); National Psoriasis Foundation – I(Grants/Research Funding); Pfizer Inc. – A(H); UCB – C(H);
  • Gierbolini, Athena: no financial relationships exist with commercial interests.
  • Goldberg, Stephanie, MD: no financial relationships exist with commercial interests.
  • Hamzavi, Iltefat H., MD: AbbVie – A(NC); Bayer – I(Grants/Research Funding); Clinuvel – I(Fees); Eli Lilly and Company – I(Grants/Research Funding); Estee Lauder – I(Fees); Ferndale Laboratories, Inc. – I(Fees); Galderma Laboratories, L.P. – I(Fees); Global Vitiligo Foundation – B(NC); Hidradenitis Suppurativa Foundation – B(NC); Incyte Corporation – I(Grants/Research Funding); Janssen Biotech – I(Grants/Research Funding); Lenicura – I(EQ); Pfizer Inc. – I(Fees);
  • Jemec, Gregor B.E., MD: AbbVie – A(H), I(Grants/Research Funding); Astion Pharma – C(H); Desitin Arzneimittel GmbH – Speaker/Faculty Education(NC); InflaRx GmbH – A(H), C(H), I(Grants/Research Funding); Janssen-Ortho Inc. – I(Grants/Research Funding); LEO Pharma, US – I(Grants/Research Funding); Michelson Diagnostics Ltd. – I(NC); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); UCB – A(H);
  • Lowes, Michelle Anne, MBBS, PhD: AbbVie – C(Fees); Almirall – C(Fees); BSN Medical – C(Fees); Incyte Corporation – C(Fees); Johnson and Johnson – A(Fees); XBiotech – C(Fees);
  • Naik, Haley, MD: AbbVie – I(Grants/Research Funding);
  • Parks Miller, Angela: AbbVie – A(H), C(Fees); Hidradenitis Suppurativa Foundation – E(S); Hope for HS – F(NC);
Schedule
Monday, March 4
9:00 AM
Dr. Hamzavi / Introduction and Welcome
9:05 AM
Dr. Alavi / Diagnosis of hidradenitis suppurativa & phenotypes
9:20 AM
Dr. Lowes / Pathogenesis of hidradenitis suppurativa
9:35 AM
Dr. Naik / Medical treatment of hidradenitis suppurativa
9:55 AM
Parks-Miller / Lifestyle modifications & support groups for hidradenitis suppurativa
10:10 AM
Dr. Lowes, Dr. Alavi, Parks-Miller, and Dr. Naik / Question & Answer
10:25 AM
Dr. Garg / Comorbidities of hidradenitis suppurativa
10:40 AM
Dr. Hamzavi / Laser and light treament of hidradenitis suppurativa
11:00 AM
Goldberg / Surgical treament of hidradenitis suppurativa
11:20 AM
Dr. Jemec / Practical approach to managing HS patients
11:40 AM
Dr. Jemec, Dr. Garg, Goldberg, and Dr. Hamzavi / Question & Answer
Event Details
  • Date
    Monday, March 4
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 207A
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Michelle Anne Lowes, MBBS, PhD
Speakers
  • Afsaneh Alavi, MD, FAAD
  • Amit Garg, MD, FAAD - Handout
  • Angela Parks Miller
  • Athena Gierbolini
  • Gregor B.E. Jemec, MD
  • Haley Naik, MD, FAAD - Handout
  • Iltefat H. Hamzavi, MD, FAAD
  • Stephanie Goldberg, MD